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Background. There is emerging evidence to support the use of granulocyte colony-stimulating factor (G-CSF) therapy in patients
with acute ischemic stroke. Aims. To explore feasibility, safety, and preliminary eﬃcacy of G-CSF therapy in patients with acute
ischemic stroke. Patients and Method. In randomized study, 10 patients with acute ischemic stroke were recruited in 1:1 ratio
to receive 10µg/kg G-CSF treatment subcutaneously daily for ﬁve days with conventional care or conventional treatment alone.
Eﬃcacy outcome measures were assessed at baseline, one month, and after six months of treatment included Barthel Index (BI),
National Institute of Health Stroke Scale, and modiﬁed Rankin Scale. Results. One patient in G-CSF therapy arm died due to
raised intracranial pressure. No severe adverse eﬀects were seen in rest of patients receiving G-CSF therapy arm or control arm.
No statistically signiﬁcant diﬀerence between intervention and control was observed in any of the scores though a trend of higher
improvement of BI score is seen in the intervention group. Conclusion. Although this study did not have power to examine eﬃcacy,
it provides preliminary evidence of potential safety, feasibility, and tolerability of G-CSF therapy. Further studies need to be done
on a large sample to conﬁrm the results.
1.Introduction
Stroke is an important cause of mortality and morbidity
worldwide [1]. Despite recent advances in antithrombotic
treatment, poststroke disability has signiﬁcant economic and
social burden. As brain has limited capacity to regenerate,
there is the need to develop therapeutic strategies to enhance
neuroprotection and repair. Autologous stem-cell transplan-
tationhasbeentriedbuthaslimitedduetounproveneﬃcacy
and lack of available facility widespread [2].
Currently, few treatments exist for acute stroke, com-
prising mainly aspirin and thrombolytic drugs which have
pooravailabilityinthedevelopingcountriesandverynarrow
time window for its intervention. A clear need exists to
identify new drugs. Granulocyte colony stimulating-factor
(G-CSF) is a cytokine that acts on hematopoietic stem
(CD34+) cells and stimulates proliferation, maturation, and
survival of the neutrophilic granulocyte lineage. It is widely
employed to mobilize bone marrow stem cells in patients
with leukaemia treated with bone marrow transplantation
and chemotherapy-induced neutropenia for last two decades
[3]. Since Sch¨ abitz et al. [4] observed infarct size-reducing
capabilities of G-CSF in animal stroke model, a number
of preclinical investigations were initiated to explore its
neuroprotective abilities. In later experimental studies of
cerebral ischemia, G-CSF was found to be neuroprotec-
tive via diﬀerent mechanisms, including mobilization of
haemopoietic stem cells, antiapoptosis, neuronal diﬀeren-
tiation, angiogenesis, and anti-inﬂammation [5, 6]. These
properties are particularly signiﬁcant in view of apoptosis,2 Stroke Research and Treatment
and inﬂammation has implication in the pathophysiology of
cerebral ischemic injury. In virtue of the above properties,
it was speculated that G-CSF not only inhibits neuron
death, but also generates new neuronal tissue formation. The
observation of G-CSF’s eﬀect on mobilization of stem cells
from the bone marrow initiated explorations of its potential
beneﬁt in stroke with the assumption that mobilized stem
cells may home into the injured brain.
Meta-analysis from the animal studies suggested that
G-CSF both reduces infarct size and enhances functional
recovery, and its eﬀe c ti sp r e s u m a b l yd o s ed e p e n d e n t[ 7].
Three small clinical trials investigated the safety and
feasibility and eﬃcacy of stem cell mobilization by G-CSF in
7, 24, and 44 patients at diﬀerent doses of G-CSF with acute
ischemic stroke patients, respectively [8–10]. In all studies,
G-CSF therapy appeared to be safe and reasonably well
tolerated. Summary of G-CSF published studies in stroke
patientsaregiveninTable1.ThereareseveraltrialsofG-CSF
therapy in stroke ongoing across the world. Results of these
trialswillbehelpfulinknowingtheeﬃcacyofG-CSFtherapy
in stroke. Building on preclinical and clinical data suggesting
functional and survival beneﬁt using granulocyte colony-
stimulating factor (G-CSF) in this fashion, we undertook a
single centre, randomized, open-label pilot trial in patients
with acute ischemic stroke. Moreover, the therapy is less
invasive,relativelyinexpensive(comparedtort-PA),ethically
acceptable, and has long therapeutic window. The aim of the
present study was to assess the safety and eﬃcacy of G-CSFs
at 10µg/kg G-CSF in patients with acute ischemic stroke and
to assess the eﬀect on circulating stem cell and blood cell
counts.
2. Methods
2.1. Participants. All patients with acute ischemic stroke
attending the neurology services at All India Institute of
Medical Sciences, New Delhi, between January 2008 and
May 2008, were screened for eligibility of this study. Patients
with stroke (deﬁned as rapidly developing clinical symptoms
and/orsignsoffocallossofcerebralfunction,withsymptoms
lasting more than 24 hours with no apparent cause other
than that of vascular origin) were considered eligible if
they fulﬁlled all of the following: age between 30 and 75
years, within seventh day from onset, computed tomography
and/or magnetic resonance imaging scan of the brain show-
ing no haematoma, and relevant lesions within the middle
cerebral artery territory, Glasgow coma scale (GCS) score
above eight (eye and motor score of more than six in patients
with aphasia), Barthel index (BI) score of 55 or less, National
Institute of health stroke Scale (NIHSS) score between 7 and
20, and inability to walk unaided or raise upper limb by 90
degree and clinically stable. A patient were deﬁned as stable
when they had normal respiration, was afebrile, had blood
pressure less than mean arterial pressure of 125mmHg (but
no hypotension deﬁned as systolic BP <90mmHg), and had
fasting venous blood sugar level less than 200mg% along
with normal serum urea and electrolytes.
Patients meeting the above criteria were excluded from
the study if they had any one of the following: lacunar syn-
drome, intracranial pathologies (e.g., tumor and infection),
intubation, comorbidity likely to limit survival to less than
three years, for example, malignant diseases, hepatic or renal
failure, prestroke disability leading to dependence on others
for activities of daily living, haematological dysfunction (a
history of major bleeding requiring blood transfusion or of
leukopenia thrombocytopenia), inaccessibility for followup,
pregnancy or unwillingness to provide written informed
consent (by self or next of kin). The study was approved by
the Institute Ethics Committee of AIIMS.
2.2. Study Design. This was a 12-month duration, random-
ized, open-label, parallel-group study. Eligible consenting
subjects were randomly assigned in a 1:1 ratio to G-CSF
therapy for ﬁve days along with conventional management
or conventional management alone. Patients were randomly
allocated to one of the two groups, by use of a computer-
generated simple randomization table. The randomized allo-
cation of groups was performed by a blinded, independent
coordinator not related to patient care in the study via
telephonic call. Subsequent to random allocation to groups,
intervention was not blinded.
All patients were evaluated according to a protocol that
included demographic data, medical history, stroke risk fac-
tors, and neurological examination. To determine stroke se-
verity, we used the BI (scores range from 0 to 100, with lower
scores indicating increasing severity) as an index of func-
tional recovery and NIHSS score (scores range from 0 to
42, with higher scores indicating increasing severity) as an
index of neurological deﬁcit. After all of the data had been
recorded, patients were randomized to receive either sub-
cutaneous human recombinant G-CSF (ﬁlgastrim, Grafeel,
India) 10µg/kg subcutaneously administered daily for ﬁve
days along with conventional treatment or conventional
treatment alone. Intervention was given within two hours
of randomization. We assessed safety of subcutaneous G-
CSF infusion by recording the development of immediate
or delayed reactions. Immediate reactions included allergic
reactions (tachycardia, fever, skin eruption, and leukocyto-
sis). Leukocyte counts were measured on day one, three, ﬁve,
and seven from blood samples. One week after the initiation
of therapy, patients were discharged unless clinically war-
ranted.
After discharge, all of the patients were followed up
at one month; modiﬁed Rankin scale (scores range from
zero to six, with higher scores indicating increasing severity)
as an index of functional recovery, along with BI and
NIHSS, was recorded. Adverse events elicited included bone
pain, headache, liver dysfunction, myocardial infarction,
recurrence of stroke, and peripheral arterial thromboses.
Subsequently, all of the patients were followed up at six and
twelve months in the outpatient department, and neurolog-
ical functions were assessed using all three scales. The 12-
month scores from the BI, NIHSS, and mRS were used to
assess treatment eﬃcacy. Improvement was deﬁned as the
percentage change in mean group scores between baselineStroke Research and Treatment 3
Table 1: Summary of published studies of G-CSF therapy in stroke patients.
Author (year) Trial design/phase G-CSF regimen Time after stroke Patients
(intervention/control) Comments
Floel et al.
(2011)
Randomized
controlled trial
10µg/kg s/c for
10 days
4 months after 21 Intervention 20
Placebo
Feasibility and safe and
reasonable tolerable in chronic
stroke patients
Sch¨ abitz et al.
(2010)
Randomized,
placebo-controlled
30µg/kg,
90µg/kg,
135µg/kg,
180µg/kg
Within 12 hours
14/ Placebo
8/30µg/kg
7/90µg/kg
8/135µg/kg
7/180µg/kg
Well tolerated even in higher
doses and Treatment eﬀect in
patients with higher volume of
lesion size (14–17cm3)a t
baseline
Shyu et al.
(2006)
Single blind
controlled/pilot
15µg/kg/day s/c
for 5 days
Within 7 days
7 Intervention
15µg/kg/day s/c
for 5 days 3 Control
No thrombotic complications,
a n di m p r o v e do u t c o m ei nG - C S F
group
NIHSS 59% in G-CSF group,
36% in controls group BI 120%
in G-CSF group, and 60% in
controls group
Sprigg et al.
(2006)
Double-blind
placebo-
controlled/pilot
Dose escalation
1–10µg/kg s/c
for 1 or 5 days
7–30 days
12/Placebo
4/1µg/kg (single dose)
4/3µg/kg (single dose)
4/10µg/kg (single dose)
4/1µg/kg (ﬁve dose)
4/3µg/kg (ﬁve dose)
4/10µg/kg (ﬁve dose)
No diﬀerence in SAEs although
non signiﬁcant increase in
infection rates in active group
Signiﬁcant increase in CD-34+
with 10µg/kg (ﬁve dose) at day
ﬁve
Zhang (2006)
Double-blind
placebo-
controlled/pilot
2 µg/kg/day s/c
for 5 days
Within 7 days 15 Intervention
30 Control
No diﬀerence in adverse events
reported and signiﬁcant
r e d u c t i o ni nN I H S S
and 12 months. To evaluate tumor formation as a delayed
complication, we performed a regular physical examination
including visual inspection of skin and oral mucosa, a
follow-up magnetic resonance imaging brain at one month
and six-months, and whole body FDG-positron emission
tomography at the end of 12 months.
2.3. Statistical Analysis. Analysis was done after completion
of six-month followup. The primary analyses of eﬃcacy and
safety were performed on the intention to treat analysis.
This included all patients who were randomized to receive
treatment. Baseline characteristics and diﬀerences between
G-CSF and control groups with diﬀerent outcome measures
were analyzed using Mann-Whitney U-tests. Data was ana-
lyzed using the SPSS statistical package, version 17.0 (SPSS,
Chicago, IL, USA).
3. Results
Between January 2008 and May 2008, a total of 19 patients
with acute ischemic stroke were screened for eligibility
(Figure 1). Of those 19 patients, nine were excluded, as four
had intracranial bleed, three had improved Barthel index,
and two refusals to consent by caregivers. All ten consecutive
patients who were found eligible were randomly assigned
to G-CSF or control. At baseline, ﬁve patients were in G-
CSF group and ﬁve patients were in control group. In G-
CSF group, all patients except one completed 5-day course
of G-CSF therapy. One patient had clinical deterioration on
day three of G-CSF therapy, so intervention was withheld,
and patient died on eighth day after randomization. None
of the patients showed deterioration in NIHSS, BI, or mRS
during the followup. No patient developed liver or renal
dysfunction. PET scan at one year did not show any evidence
of tumor formation.
As per protocol numbers of patients completed trial
were four in G-CSF arm and ﬁve in control arm. There
were no losses to followup over the study period. Baseline
characterises of individual patients is summarized in Table 2.
There was no signiﬁcant diﬀerence in baseline characteristics
between the two groups (Table 3).
Improvement in BI, NIHSS, and mRS did not diﬀer
signiﬁcantly between the G-CSF and control groups, Figures
2, 3,a n d4. Although a trend of higher improvement of BI
score is seen in the intervention group, the diﬀerence did not
achieve statistical signiﬁcance.
Rise in maximum leukocyte count at hospital stay from
baseline and clinical outcome score in individual patients
wise assessed at diﬀerent time interval is given in Table 4.
There was statistically signiﬁcant rise in the mean leukocyte
countandalkalinephosphataselevelsintheinterventionarm
as compared with baseline and to control arm (P<0.005
a n d0 . 0 1 ,r e s p . ) .R i s ei nm e a nl e u k o c y t ei sr e p r e s e n t e di n
Figure 5. Rise in peripheral blood CD-34 count did not diﬀer
signiﬁcantly between the G-CSF and control groups.
G-CSF therapy was reasonably well tolerated. Of the ﬁve
patients receiving G-CSF, one reported mild bone pain that4 Stroke Research and Treatment
2 Refused to consent
Assessed for eligibility (n = 19)
Excluded (n = 9)
4 Had intracranial bleed
3 Had improvedBarthel index
Excluded from analysis due to death
up Lost to follow (n = 0) up Lost to follow (n = 0)
Allocated to G-CSF (n = 5)
Received allocated intervention (n = 4)
1
1
did not completed G-CSF 5 days due to
clinical deterioration
Allocated to Control (n = 5)
Analysed (n = 5) Analysed (n =4)
Excluded from analysis (n = 0)
Allocation
Analysis
Followup
Randomized(n = 10)
Enrollment
Figure 1: Enrolment, randomization, and analysis of patients.
lastedonedayandsubsidedspontaneously.OnepatientinG-
CSF arm had deep venous thrombosis in left lower limb that
required hospitalisation and subsided with treatment. There
were no aggravations of stroke symptoms during the course
of therapy and hospital stay. There was no aggravation of
limb weakness, speech impairment, or sensory impairment
during the 12-month followup in either study group. No
severe adverse eﬀects were seen in any of patients receiving
G-CSF therapy arm or control arm.
4. Discussion
This is the ﬁrst preliminary randomized controlled study to
explore safety and preliminary eﬃcacy of G-CSF in patients
with stroke from India. In accordance with previous studies,
we found G-CSF therapy safe and well tolerated in ﬁve
patients with acute stroke [8–10].
We failed to ﬁnd eﬀectiveness of G-CSF in improving
neurologic outcome in patients with acute ischemic stroke.
With only ﬁve patients in each arm, the pilot study was not
designed to have the power to detect outcome diﬀerences
between the groups.
Two points deserve some comments.
(1) Optimal dose of G-CSF:s e v e r a ls t u d i e sh a v eb e e n
completed at diﬀerent doses of G-CSF. (Table 1.) Our
120
100
80
60
40
20
0
1 2 3
30 32
66.25
63
81.25
76
Intervention
Control
Figure 2: Mean Barthel index scale score at baseline, one month
and six months of the intervention and control group. 1; baseline,
2; one month, 3; six months, BI scores range from 0 to 100, with
lower scores indicating increasing severity.
study suggest that G-CSF at dose of administered
10µg/kg daily for ﬁve days appeared to be safe andStroke Research and Treatment 5
Table 2: Patient’s characteristics.
Case no. 12345 6 7891 0
Allocation Control G-CSF Control G-CSF G-CSF G-CSF Control Control Control G-CSF
Days b/w onset of
stroke and
randomization
34744 3 6215
Age/sex 56 45 35 45 40 55 55 65 30 38
Territory and side Rt MCA Rt MCA Lt MCA Lt MCA Rt MCA Both MCA & ACA Rt MCA Lt MCA Lt MCA Rt MCA
Previous stroke −−−−− − −+ −−
GCS baseline 15.00 15.00 15.00 14.00 15.00 14.00 15.00 11.00 15.00 15.00
Hypertension + −−−− + −−−−
Diabetes −−−−− − −−−−
Dyslipidemia − + −−− + −−−−
Smoker −−−−− + − + −−
Table 3: Summary of patient characteristics and eﬃcacy outcomes (diﬀerence between six-month and baseline scores).
Intervention n = 5C o n t r o l n = 5 P-value
Age in years∗ 44 ± 6.5 (38 to 55) 48 ± 14.9 (30 to 65) 0.63
GCS score∗ 14.7 ± 5 (14 to 15) 14.2 ± 1.7 (11 to 15) 0.65
Days b/w onset of stroke and randomization∗ 4 ± 2.44 (1 to 7) 4 ± 0.7 (3 to 5) 0.87
NIHSS score∗† 14 ± 3.9 (8 to 19) 11.0 ± 3.39 ( 7 to 15) 0.23
Mean diﬀerence of NIHSS from six months to baseline −7.0 −6.75 0.90
BI score∗‡ 25 ± 17.67 (5 to 45) 32 ± 21.09 (15 to 55) 0.58
Mean diﬀerence of BI from Six months to baseline 51.25 44 0.59
Mean diﬀerence of mRS from six months to one month −0.5 −0.4 0.79
∗Figures represent mean ± SD (range) or numbers.
†NIHSS scores range from 0 to 42, with higher scores indicating increasing severity.
‡BI scores range from 0 to 100, with lower scores indicating increasing severity.
§mRs score range from 0 to 6, with higher scores indicating increasing severity.
Table 4: Leukocyte counts at baseline and maximum count during hospital stay and clinical score during baseline one month, six months,
and 12 months.
Total leukocyte count Stroke scale scores at baseline, one month/six months and 12 months
Patient no. Baseline Maximum during
hospital stay NIHSS BI mRS
G-CSF group
1 13400 40800 14/10/9 10/35/65 4/4
2 12400 — 19/−/− 5/−/−− /−
3 7500 35400 14/9/6 45/80/85 3/3
4 7600 39200 15/7/3 25/90/95 3/2
5 8400 33400 8/9/5 40/60/80 4/3
Control group
1 7000 7000 13/10/5 15/35/55 4/4
2 13500 13500 12/10/4 55/60/75 4/3
3 8500 10400 15/12/− 20/30/55 4/4
4 7300 7300 7/2/2 55/100/100 2/1
5 10100 10100 8/4/2 15/90/95 2/2
NIHSS: National Institutes of Health stroke scale, BI: Barthel index, mRS: modiﬁed ranking scale
NIHSS score range from 0 to 42 (lower score represents better outcome and higher score represents worse outcome)
BI score range from 0 to 100 (Higher score represents the better outcome and lower score represents the worse outcome)
mRS score range from 0 to 6 (lower score represents better outcome and higher score represents worse outcome).6 Stroke Research and Treatment
Intervention
Control
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8
6
4
2
0
1 2 3
12.75
10
9.25
6.5 5.75
3.2
Figure 3: Mean National Institute of Health scale score, at baseline,
one month and six months of the intervention and control group.
1; baseline, 2; one month, 3; six months, NIHSS scores range from
0 to 42, with higher scores indicating increasing severity.
4
3.5
3
2.5
2
2
1.5
1
1
0.5
0
3.5
3
3.2
2.8
Intervention
Control
Figure 4: Mean modiﬁed Rankin scale score at one month and six
months of the intervention and control group. 1; one month, 2; six
months, mRs score range from 0 to 6, with higher scores indicating
increasing severity.
reasonably well tolerated, and there was higher trend
of improvement in Barthel index score in interven-
tiongroupcomparedtocontrol.Previousstudies[10,
11] have used 10µg/kg daily for ﬁve days protocol. To
allow comparison of our results with the published
studies and in future to facilitate meta-analyses, we
have followed the same protocol. Several studies are
ongoing with diﬀerent doses of G-CSF in stroke and
results of all studies will be helpful to determine the
dose-response gradient of G-CSF. CD-34+ cells in
peripheral blood increases signiﬁcantly after G-CSF
injection of 10µg / k gf o rc o n s e c u t i v eﬁ v ed a y s[ 10].
There was dose-dependent beneﬁcial eﬀect observed
40
35
30
25
20
15
10
5
0
Baseline Day 1 Day 3 Day 5
Intervention
Control
×103
Figure 5: Mean Leukocyte count of intervention and control
groups at Baseline, Day 1, Day 3, and Day 5.
in treatment with patient with DWI lesion >14–
17cm3 [8]. Our study provide basis for the second
trial with the dose of 10µg/kg daily for ﬁve days. In
view of similar ﬁndings from other G-CSF trials [8–
10] in stroke patients, G-CSF therapy appeared safe
and reasonably well-tolerated. Our data also suggest
that rise in the leukocyte and alkaline phosphatase at
this dose is not challenging in acute stage of stroke.
There is clear need for identiﬁcation of optimal dose
of the G-CSF at which its eﬀects is highest in improv-
ing functional outcome in stroke. More studies are
needed to determine the optimal dose of G-CSF.
(2) Timing of G-CSF injection: a therapeutics time win-
dow for intervention is a major promise of G-CSF
therapy. Time of intervention used in clinical studies
is summarised in Table 1. At present-time treatment
for stroke, particularly thrombolytic therapy with
tissueplasminogenactivatorischallengingbecauseof
its short time window of eﬃcacy therefore, there is a
clear need for novel and eﬀective treatment options,
with a longer time window. Shyu et al. [9]t e s t e d
within seven days of onset of stroke and found there
were consistent trend towards improvement in neu-
rologicalfunctionalrecoveryinG-CSFgroup.CD34+
stem cells also eﬀectively mobilized and appeared to
be safe and well tolerated after G-CSF injection when
treatment is delayed for month in ischemic stroke
patients [10]. Wider therapeutic window would be
a signiﬁcant achievement for stroke, since patients
often does not reach hospital—nor is the disease
often diagnosed until later than 3 hours after onset.
Sch¨ abitz et al. [8] 2010 (AXIS trial) tested within 12
hours of onset of stroke and found it is well tolerated
and more eﬀective with higher doses in patients withStroke Research and Treatment 7
largerlesionvolume.TimingofGCSFadministration
is likely to inﬂuence its neuroprotective eﬀects.
Mechanism of action of G-CSF may primarily on
neurons; it is likely that the earlier treatment may
have more potent neuroprotective eﬀect. Our study
suggeststhattreatmentwithG-CSFwithinsevendays
of onset of stroke appeared to be safe and reasonably
well tolerated.
Basedontheﬁndingsofthepilotstudy,Drug-Controller-
General of India has approved our multicentric, phase I/II
safety and eﬃcacy, randomized controlled trial of G-CSF
with 200 sample size of patients. Our planned clinical trial
is to establish safety and explore eﬃcacy of G-CSF therapy in
acutestrokepatients.Theprotocolisunderconsiderationfor
fundingintheDepartmentofBiotechnology,Governmentof
India.
Limitation of Study. The study is with small number of sam-
ple size; however, other studies are ongoing and published in
international journals with small number of sample sizes.
Inconclusion,G-CSFadministered10µg/kgdailyforﬁve
days appeared to be safe and well tolerated in ﬁve patients
aged 35–75 years with acute ischemic stroke in accordance
with other published G-CSF trials in stroke patients. How-
ever, in view of limited sample size, the results of the
current study must be interpreted with caution. Further,
large, adequately powered, multicenter randomized placebo-
controlled, blinded trials are needed to test the eﬃcacy of G-
CSF in patients with acute ischemic stroke.
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